Abstract
Central deletion of “self-reactive” T cells has been the textbook paradigm for inducing “self-tolerance” in the periphery and the concept of a role of T cell-mediated suppression in this process has long been controversial. A decisive shift in the opinion on suppressor T cells has lately occurred with the observations of Sakaguchi’s group that linked a class of CD4+CD25+ T cells to the prevention of autoimmunity from neonatal thymectomy in mice. These CD4+CD25+ T cells have been named T regulatory (Treg) cells. They are believed to be selected in the thymus as an anti-self repertoire. Hence they were referred to as natural T regulatory (nTreg) cells. Presently, in addition to their role in autoimmunity, they are believed to exert regulatory function in infection, in transplantation immunity as well as in tumor immunity. In contrast to these nTreg cells, another class of CD4+ Treg cells also exercises regulatory function in the periphery. These Treg cells are also CD4+ T cells and after activation they also become phenotypically CD4+CD25+. They are, however induced in the periphery as Treg cells. Hence, they are termed as induced Treg (iTreg) cells. There are major differences in the biology of these two types of Treg cells. They differ in their requirements for activation and in their mode of action. Nonetheless, evidence indicates that both nTreg cells and iTreg cells are involved in the control of tumor immunity. The question of how to circumvent their regulatory constraints, therefore, has become a major challenge for tumor immunologists.
Similar content being viewed by others
Abbreviations
- Treg:
-
T regulatory
- nTreg:
-
Natural Tregulatory
- iTreg:
-
Inducible T regulatory
- Ts:
-
T suppressor
- APC:
-
Antigen presenting cell
- CTL:
-
Cytolytic T lymphocytes
- MHC:
-
Major histocompatibility complex
- IL:
-
Interleukin
- IFN:
-
Interferon
- TAA:
-
Tumor associated antigen
References
Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723
Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247
Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531
Shevach EM (2001) Certified professionals: CD4+CD25+ suppressor T cells. J Exp Med 193:F41
Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: I. Requirement of Lyt-1 effector cells for oocyte damage after adoptive transfer. J Exp Med 156:156
Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: II. Requirement of Lyt-1 effector cells in normal female mice for the prevention of oophoritis. J Exp Med 156:1577
Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T (1985) Organ specific autoimmunie diseases induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 161:72
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151
Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69
North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1
Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888
Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893
Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961
Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 26:455
Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki Y, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahasi T (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18
Piccirillo CA, Shevach EM (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81
O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nature Med 10:801
Thompson C, Powrie F (2004) Regulatory T cells. Curr Opin Pharmacol 4:408
Bach JF (2003) Regulatory T cells under scrutiny. Nature Rev Immunol 3:189
Ehrlich P (1909) Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand Der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273
Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78
Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725
Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175
Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 54:187
Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4:401
Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329
Marincola FM, Jaffee EM, Hiclin DJ, Ferrone S (2000) Escape of human solid tumors from T cell-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181
Pawlec (2004) Tumor escape from the immune response. Cancer Immunol Immunother 53:843
Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy; possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844
Anichini A, Vigetti C, Mortini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855
Whiteside TL (2004) Down-regulation of the z-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865
Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of Th2 type CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells, in vitro: Implications in designing tumor vaccines. J Immunol 162:5576
Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and down-regulation of cytotoxic immune response against autologous human cancer. J Immunol 138:1987
Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytolytic response. J Immunol 145:2359
Mukherji B, Chakraborty NG, Sivanandham M (1990) T cell clones that react against human tumors. Immunol Rev 116:33
Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature 389:737
Roncarolo MG, Bachetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68
Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T cells response and tumor vaccine induced CTL in human melanoma. Human Immunol 65:794
Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunottherapy. Immunity 20:107
Shimizu J. Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211
Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukine-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128
Gallimore A, Sakaguchi S (2002) Regulation of tumor immunity by CD25+ T cells. Immunology 107:5
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocytes-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J Exp Med 194:823
Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2:1
Wei-Zen W, Morris GP, Kong Yi-chi M (2004) Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73
Tanaka H, Tanaka J, Jorgen K, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207
Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine rejection antigens. Eur J Immunol 32:3267
Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients inhibit autologous T cell proliferation. J Immunol 168:4272
Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+D25+ regulatory T cells suppress tumor immunity sensitive to cyclophosphamide which allows immunotherapy in established tumors to be curative. Eur J Immunol 34:336
Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931
Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 20:771
Liyanage UK, Moore TT, Joo HG, Tanaka Y, Hermann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756
Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606
Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2003) Immunosuppressive regulatory T cells ate abundant in tumor lymphocytes of Hodgkins lymphoma. Blood 103:1755
Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85
Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:167
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942
Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25+ regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444
Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 171:5678
Thronton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287
Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: Production of CD25+CD4+ Naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317
Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD(+)CD25(+high) regulatory T cell function. J Immunol 169:6210
Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger R (2004) Large-scale in vitro expansion of polyclonal human CD4(+) CD25high regulatory T cells. Blood 104:895
Thronton AM, Picirillo CA, Shevach EM (2004) Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 24:366
Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519
Malek TR (2003) The main function of IL-2 is to promote the development of regulatory T cells. J Leukoc Biol 74:961
Suri-Payer E, Cantor H (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. J Autoimmun 16:115
Asseman C, Mauze S, Leach M, Coffman Rl, Powrie F (1999) An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995
Balkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sachs DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502
Takahashi T, Tagami T, Yamazuki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Dominant immunologic self-tolerance by CD4+CD25+ regulatory T cells constitutively expressing CTLA-4. J Exp Med 192:303
Read S, Maimstrom S, Powrie F (2000) CTLA-4 plays an essential role in the function of CD4+CD25+ regulatory cells which control intestinal inflammation. J Exp Med 192:295
Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface bound transformation growth factor beta. J Exp Med 194:629
Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S (2002) Phenotype localization and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 196:379
Levings MK, Bacchetta R, Schulz U, Roncarolo MG (2002) The role of IL-10 and TGF beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263
Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137
Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538
Misra N, Bayry J, Lacroix-demazes S, Kazatcchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676
Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355
Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B (2004) Rescuing melanoma epitope specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunoterapy. J Immunol 173:6017
North RJ (1982) Cyclophosphamode-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063
North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90
Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T -cells. Cancer Res 48:1671
Michiels J-P H, Reilly RT, Emens LA, Ercollini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immmune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689
Shevach EM (2002) CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389
Cohn M (2004) Whither T-suppressors: if they did not exist would we have to invent them? Cell Immunol 227:81
Acknowledgements
The authors thank Robert B Clark for a critical reading of the manuscript and for helpful suggestions. This work was supported by PHS grants CA 88059 and CA83130
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chattopadhyay, S., Chakraborty, N.G. & Mukherji, B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 54, 1153–1161 (2005). https://doi.org/10.1007/s00262-005-0699-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-005-0699-9